Nordic Nanovector - Financial Calendar 2021
OSLO, Norway, Dec. 21, 2020 /PRNewswire/ --
Nordic Nanovector ASA (OSE: NANOV) provides an update for its Financial Calendar for 2021.
18 February 2021 - Quarterly Report - Q4'2020 / FY'2020
15 April 2021 - Annual General Meeting
26 May 2021 - Quarterly Report - Q1'2021
27 August 2021 - Quarterly Report - Q2'2021 / 1H'2021
18 November 2021 - Quarterly Report - Q3'2021
The dates are subject to change. The time and location of the presentations will be announced in due time.
This information is published pursuant to the requirements set out in the Continuing obligations.
For further information, please contact:
Malene Brondberg, CFO
Cell: +44 7561 431 762
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector